Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

1680 participants were randomized over the recruitment period in MAPT study. A total of 1290 participants were recruited in the 7 University Hospital centers, and 390 participants in the 6 memory clinics around Toulouse Gerontopole / Alzheimer Disease research clinical center. The first randomization was on May 30, 2008, and the targeted number of randomized participants was reached on February 24, 2011; 2595 subjects were finally screened, of which 1680 fulfilled the eligibility criteria which represents 64.8%. Approximately, one quarter of screened people refused to participate after the detailed presentation of the study and 4.3% were still interested in participating but missed for unknown reasons the baseline visit even after repeated contacts. Of the 1810 subjects who signed the consent for participating to the study at the baseline visit, 130 (7.1%) were excluded because one of the eligibility criteria was not satisfied. Interestingly, the higher percentage of randomizations compared to screened participants is the personal contact source; almost 85 % of screened participants entered in the study. In an equivalent way, Medias and conferences are efficient recruiting sources to enrol volunteers in the study. Unexpectedly, only about 60% of screened participants from the hospital and GP sources were randomized and 33.2% from health care services. Almost a quarter of the randomized participants come from the hospital outpatients clinics and approximately 20% from public conferences. A total of 1128 contacts yielded to 556 screened volunteers and 345 randomized participants in the coordinating center of Toulouse. Thus, 30 % of contacts were recruited.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Carrié, I., van Kan, G. A., Gillette-Guyonnet, S., Andrieu, S., Dartigues, J. F., Touchon, J., et al. (2012). Recruitment strategies for preventive trials. The MAPT study (MultiDomain Alzheimer Preventive Trial). The journal of nutrition, health & aging. https://doi.org/10.1007/s12603-012-0046-8

Vancouver

Carrié I, van Kan GA, Gillette-Guyonnet S, Andrieu S, Dartigues JF, Touchon J, et al. Recruitment strategies for preventive trials. The MAPT study (MultiDomain Alzheimer Preventive Trial). The journal of nutrition, health & aging. 2012. doi:10.1007/s12603-012-0046-8. PMID: 22499458.

BibTeX

@article{carrie2012-22499458,
  author  = {Carrié, I. and van Kan, G. A. and Gillette-Guyonnet, S. and Andrieu, S. and Dartigues, J. F. and Touchon, J. and Dantoine, T. and Rouaud, O. and others},
  title   = {{Recruitment strategies for preventive trials. The MAPT study (MultiDomain Alzheimer Preventive Trial)}},
  journal = {The journal of nutrition, health \& aging},
  year    = {2012},
  doi     = {10.1007/s12603-012-0046-8},
  pmid    = {22499458},
  url     = {https://doi.org/10.1007/s12603-012-0046-8}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This paper describes recruitment strategies for the MAPT preventive trial and reports how participants were enrolled. It contains no treatment or prevention results, so it has no implications for treating, curing, or preventing Alzheimer's disease.

Study details

How this study scored 59/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 0 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 3 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomised / blinded 1 of 2; Times cited 4 of 7; Citations per year 2 of 5; Impact for its field and year 4 of 6; Cited by studies here 2 of 6; Still being cited 1 of 4; Senior author's track record 4 of 4; Institution's track record 2 of 3; Multi-centre collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 59 of 100.59 of 100 points earned41 not earned

Published in a peer-reviewed journal. Scored zero for study design because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (The journal of nutrition, health & aging)
Journal's citation record 1 / 4 The journal of nutrition health & aging: journal h-index 122 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2012 — within 20 year(s) of the newest study here
Sample size 3 / 4 1,680 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomised / blinded 1 / 2 Randomised (as stated in the record)
Times cited 4 / 7 Cited 68 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 4.2 citations a year over 16 year(s) since 2012
Impact for its field and year 4 / 6 Cited 8.7× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 4 other studies in this library
Still being cited 1 / 4 Cited 4 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Bruno J. Vellas: h-index 135 (OpenAlex, whole career)
Institution's track record 2 / 3 Inserm: institution h-index 1,988 (OpenAlex)
Multi-centre collaboration 3 / 3 OpenAlex lists 14 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 22499458)
Free to read 2 / 2 Free to read
Total 59 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

4 studies in the alzhub library list this one in their references.

Related studies in Treatments

Also tagged “double-blind”

783 studies in the library carry the topic tag “double-blind”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Similar studies

More on Treatments

See all studies in Treatments →